Multidrug resistance (MDR) reduces the efficacy of chemotherapy. Besides inducing the expression of drug efflux pumps, chemotherapy treatment alters the composition of the tumor microenvironment (TME), thereby potentially limiting tumor-directed drug delivery. To study the impact of MDR signaling in cancer cells on TME remodeling and nanomedicine delivery, we generated multidrug-resistant 4T1 triple-negative breast cancer (TNBC) cells by exposing sensitive 4T1 cells to gradually increasing doxorubicin concentrations. In 2D and 3D cell cultures, resistant 4T1 cells are presented with a more mesenchymal phenotype and produced increased amounts of collagen. While sensitive and resistant 4T1 cells showed similar tumor growth kinetics in vivo, the TME of resistant tumors was enriched in collagen and fibronectin. Vascular perfusion was also significantly increased. Fluorophore-labeled polymeric (∼10 nm) and liposomal (∼100 nm) drug carriers were administered to mice with resistant and sensitive tumors. Their tumor accumulation and penetration were studied using multimodal and multiscale optical imaging. At the whole tumor level, polymers accumulate more efficiently in resistant than in sensitive tumors. For liposomes, the trend was similar, but the differences in tumor accumulation were insignificant. At the individual blood vessel level, both polymers and liposomes were less able to extravasate out of the vasculature and penetrate the interstitium in resistant tumors. In a final in vivo efficacy study, we observed a stronger inhibitory effect of cellular and microenvironmental MDR on liposomal doxorubicin performance than free doxorubicin. These results exemplify that besides classical cellular MDR, microenvironmental drug resistance features should be considered when aiming to target and treat multidrug-resistant tumors more efficiently.

Department of Nanomedicine and Theranostics Institute for Experimental Molecular Imaging University Hospital RWTH Aachen Aachen Germany

Department of Nanomedicine and Theranostics Institute for Experimental Molecular Imaging University Hospital RWTH Aachen Aachen Germany ; UT Brown Foundation Institute of Molecular Medicine UTHealth Houston Houston TX USA

Institute of Macromolecular Chemistry Czech Academy of Science Prague Czech Republic

Institute of Molecular Pathobiochemistry Experimental Gene Therapy and Clinical Chemistry University Hospital RWTH Aachen Aachen Germany

Institute of Pathology University Hospital RWTH Aachen Aachen Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf University Hospital RWTH Aachen Aachen Germany

Zobrazit více v PubMed

Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature reviews Clinical oncology. 2017;14:611–629. PubMed PMC

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nature reviews cancer. 2002;2:48–58. PubMed

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer. 2018;18:452–464. PubMed PMC

Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22:7468–7485. PubMed

Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Advanced drug delivery reviews. 2013;65:1784–1802. PubMed

Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews Drug discovery. 2008;7:771–782. PubMed

Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. Journal of controlled release. 2012;161:175–187. PubMed

Pattanshetty R, Rao MS. Cancer-related fibrosis: Prevention or treatment?–A descriptive review. Journal of Dr. NTR University of Health Sciences. 2021;10:222.

Czubryt MP. Common threads in cardiac fibrosis, infarct scar formation, and wound healing. Fibrogenesis & tissue repair. 2012;5:1–11. PubMed PMC

Murtha LA, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, Knight DA, Boyle AJ. The processes and mechanisms of cardiac and pulmonary fibrosis. Frontiers in physiology. 2017;8:777. PubMed PMC

Januchowski R, Zawierucha P, Ruciński M, Nowicki M, Zabel M. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. BioMed research international. 2014:2314–6133. PubMed PMC

Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Al Mazeedi MA, Almazyadi HA, Kallmeyer K, Dandara C, Pepper MS. The role of tumor microenvironment in chemoresistance: to survive keep your enemies closer. International journal of molecular sciences. 2017;18:1586. PubMed PMC

Theek B, Baues M, Gremse F, Pola R, Pechar M, Negwer I, Koynov K, Weber B, Barz M, Jahnen-Dechent W. Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors. Journal of controlled release. 2018;282:25–34. PubMed PMC

Ergen C, Heymann F, Gremse F, Bartneck M, Panzer U, Pola R, Pechar M, Storm G, Mohr N, Barz M. Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles. Biomaterials. 2017;114:106–120. PubMed

Doube M, Kłosowski MM, Arganda-Carreras I, Cordelières FP, Dougherty RP, Jackson JS, Schmid B, Hutchinson JR, Shefelbine SJ. BoneJ: free and extensible bone image analysis in ImageJ. Bone. 2010;47:1076–1079. PubMed PMC

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B. Fiji: an open-source platform for biological-image analysis. Nature methods. 2012;9:676–682. PubMed PMC

Taymaz-Nikerel H, Karabekmez ME, Eraslan S, Kırdar B. Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Scientific reports. 2018;8:1–14. PubMed PMC

Schrörs B, Boegel S, Albrecht C, Bukur T, Bukur V, Holtsträter C, Ritzel C, Manninen K, Tadmor AD, Vormehr M. Multi-omics characterization of the 4T1 murine mammary gland tumor model. Frontiers in oncology. 2020;10:1195. PubMed PMC

Gibalová L, Šereš M, Rusnák A, Ditte P, Labudová M, Uhrík B, Pastorek J, Sedlák J, Breier A, Sulová Z. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Toxicology in Vitro. 2012;26:435–444. PubMed

Li F, Zhou X, Zhou H, Jia J, Li L, Zhai S, Yan B. Reducing both Pgp overexpression and drug efflux with anti-cancer gold-paclitaxel nanoconjugates. PLoS One. 2016;11:1932–6203. PubMed PMC

Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S, Mondal B, Tagde P, Ahmed Z, Khan FS. Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life. 2022;12:897. PubMed PMC

Tezcan O, Gündüz U. Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells. Biomedicine & Pharmacotherapy. 2014;68:357–364. PubMed

Sarkadi B, Homolya L, Szakács G, Váradi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiological reviews. 2006;86:1179–1236. PubMed

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature reviews Drug discovery. 2006;5:219–234. PubMed

Shi J, Liu W, Fu Y, Yin N, Zhang H, Chang J, Zhang Z. US-detonated nano bombs, facilitate targeting treatment of resistant breast cancer. Journal of Controlled Release. 2018;274:9–23. PubMed

Liu J, Zhu C, Xu L, Wang D, Liu W, Zhang K, Zhang Z, Shi J. Nanoenabled intracellular calcium bursting for safe and efficient reversal of drug resistance in tumor cells. Nano Letters. 2020;20:8102–8111. PubMed

Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast cancer research and treatment. 1994;31:325–335. PubMed

Işeri ÖD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomedicine & Pharmacotherapy. 2011;65:40–45. PubMed

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC cancer. 2012;12:1–10. PubMed PMC

Li Q-Q, Xu J-D, Wang W-J, Cao X-X, Chen Q, Tang F, Chen Z-Q, Liu X-P, Xu Z-D. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clinical cancer research. 2009;15:2657–2665. PubMed

Zeltz C, Primac I, Erusappan P, Alam J, Noel A, Gullberg D. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins; Seminars in cancer biology; Elsevier; 2020. pp. 166–181. PubMed

Rimal R, Desai P, Daware R, Hosseinnejad A, Prakash J, Lammers T, Singh S. Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. Advanced drug delivery reviews. 2022:114504. PubMed

Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Annals of surgical oncology. 2007;14:3629–3637. PubMed

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clinical cancer research. 2006;12:4147–4153. PubMed

Konecny G, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang S. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. British journal of cancer. 2008;98:1076–1084. PubMed PMC

Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang L-H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer research. 2007;67:1979–1987. PubMed

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. International journal of oncology. 2007;31:277–283. PubMed

Stone RC, Pastar I, Ojeh N, Chen V, Liu S, Garzon KI, Tomic-Canic M. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell and tissue research. 2016;365:495–506. PubMed PMC

Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. The Journal of clinical investigation. 2003;112:1776–1784. PubMed PMC

Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene. 2017;36:1925–1938. PubMed PMC

Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science translational medicine. 2019;11:1946–6234. PubMed PMC

Tezcan O, Ojha T, Storm G, Kiessling F, Lammers T. Targeting cellular and microenvironmental multidrug resistance. Expert opinion on drug delivery. 2016;13:1199–1202. PubMed PMC

Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. Journal of controlled release. 2012;162:45–55. PubMed

Zhang L, Wang Y, Yang Y, Liu Y, Ruan S, Zhang Q, Tai X, Chen J, Xia T, Qiu Y. High tumor penetration of paclitaxel loaded pH sensitive cleavable liposomes by depletion of tumor collagen I in breast cancer. ACS applied materials & interfaces. 2015;7:9691–9701. PubMed

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA oncology. 2019;5:1020–1027. PubMed PMC